Please use this identifier to cite or link to this item: https://hdl.handle.net/1959.11/63632
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRowe, Christopher Wen
dc.contributor.authorWatkins, Brendanen
dc.contributor.authorBrown, Karinaen
dc.contributor.authorDelbridge, Matthewen
dc.contributor.authorAddley, Jordanen
dc.contributor.authorWoods, Andrewen
dc.contributor.authorWynne, Katieen
dc.date.accessioned2024-10-22T05:20:05Z-
dc.date.available2024-10-22T05:20:05Z-
dc.date.issued2021-
dc.identifier.citationDiabetic Medicine, 38(4), p. 1-12en
dc.identifier.issn1464-5491en
dc.identifier.issn0742-3071en
dc.identifier.urihttps://hdl.handle.net/1959.11/63632-
dc.description.abstract<p><b>Aims:</b> Hyperglycaemia following antenatal corticosteroids is common in womenwith diabetes in pregnancy, and validated algorithms to maintain pregnancy-specificglucose targets are lacking. The Pregnancy-IVI, an intravenous-insulin (IVI) algo-rithm, has been validated in gestational diabetes" however, its performance in pre-existing diabetes (Type 1 and Type 2 diabetes) is not known. We hypothesised that Pregnancy-IVI would be superior to a generic Adult-IVI protocol (prior standard of care) following betamethasone in women with pre-existing diabetes.</p><p><b>Methods:</b> A retrospective cohort study enrolled all women with pre-existing diabetes at a tertiary centre receiving betamethasone and treated with IVI according to one of two protocols: Adult-IVI (n = 73, 2014–2017) or Pregnancy-IVI (n = 62,2017–2020). The primary outcome was on-IVI glycaemic time-in-range (capillary blood glucose (BGL) 3.8–7.0 mmol/L). Secondary outcomes included time with critical hyperglycaemia (BGL > 10 mmol/L)" occurrence of maternal hypoglycaemia (BGL < 3.8 mmol/l) and incidence of neonatal hypoglycaemia (BGL ≤ 2.5 mmol/L).Analysis was stratified by diabetes type.</p><p><b>Results:</b> Overall, Pregnancy-IVI achieved a higher proportion of on-IVI time-in-range (70%, IQR 56–78%) compared to Adult-IVI (52%, IQR 41–69%, p < 0.0001).The duration of critical hyperglycaemia with Pregnancy-IVI was also reduced (2%[IQR 0–7] vs 8% [IQR 4–17], p < 0.0001), without an increase in hypoglycaemia. Glycaemic variability was significantly reduced with Pregnancy-IVI. No difference in the rate of neonatal hypoglycaemia was observed. The Pregnancy-IVI was most effective in women with Type 1 diabetes.</p><p><b>Conclusion:</b> The Pregnancy-IVI algorithm is safe and effective when used following betamethasone in type 1 diabetes in pregnancy. Further study of women with type 2diabetes is required.</p>en
dc.languageenen
dc.publisherWiley-Blackwell Publishing Ltden
dc.relation.ispartofDiabetic Medicineen
dc.titleEfficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetesen
dc.typeJournal Articleen
dc.identifier.doi10.1111/dme.14489en
dc.subject.keywordsinsulin therapyen
dc.subject.keywordspregnancyen
dc.subject.keywordsEndocrinology & Metabolismen
dc.subject.keywordspatient diabetesen
dc.subject.keywordsin&#8208en
local.contributor.firstnameChristopher Wen
local.contributor.firstnameBrendanen
local.contributor.firstnameKarinaen
local.contributor.firstnameMatthewen
local.contributor.firstnameJordanen
local.contributor.firstnameAndrewen
local.contributor.firstnameKatieen
local.profile.schoolSchool of Rural Medicineen
local.profile.emailbwatkin6@une.edu.auen
local.output.categoryC1en
local.record.placeauen
local.record.institutionUniversity of New Englanden
local.publisher.placeUnited Kingdomen
local.identifier.runningnumbere14489en
local.format.startpage1en
local.format.endpage12en
local.peerreviewedYesen
local.identifier.volume38en
local.identifier.issue4en
local.contributor.lastnameRoween
local.contributor.lastnameWatkinsen
local.contributor.lastnameBrownen
local.contributor.lastnameDelbridgeen
local.contributor.lastnameAddleyen
local.contributor.lastnameWoodsen
local.contributor.lastnameWynneen
dc.identifier.staffune-id:bwatkin6en
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.identifier.unepublicationidune:1959.11/63632en
local.date.onlineversion2021-
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
local.title.maintitleEfficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetesen
local.output.categorydescriptionC1 Refereed Article in a Scholarly Journalen
local.search.authorRowe, Christopher Wen
local.search.authorWatkins, Brendanen
local.search.authorBrown, Karinaen
local.search.authorDelbridge, Matthewen
local.search.authorAddley, Jordanen
local.search.authorWoods, Andrewen
local.search.authorWynne, Katieen
local.uneassociationYesen
local.atsiresearchNoen
local.sensitive.culturalNoen
local.year.available2021en
local.year.published2021en
local.fileurl.closedpublishedhttps://rune.une.edu.au/web/retrieve/2308ae1c-91d8-47c9-b8e0-ef9fe14dd145en
local.subject.for20203202 Clinical sciencesen
local.subject.seo2020tbden
local.profile.affiliationtypeExternal Affiliationen
local.profile.affiliationtypeUNE Affiliationen
local.profile.affiliationtypeUNE Affiliationen
local.profile.affiliationtypeUNE Affiliationen
local.profile.affiliationtypeExternal Affiliationen
local.profile.affiliationtypeExternal Affiliationen
local.profile.affiliationtypeExternal Affiliationen
Appears in Collections:Journal Article
School of Science and Technology
Files in This Item:
1 files
File SizeFormat 
Show simple item record
Google Media

Google ScholarTM

Check

Altmetric


Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.